A case study for plant-made pharmaceuticals comparing different plant expression and production systems.
Over the last decade, plant-based production of pharmaceuticals has made remarkable progress as the expression of a diverse set of proteins has been demonstrated in a range of plant crops. Although the commercial exploitation is still pending, today various plant-based expression technologies have reached significant milestones through clinical testing in humans. Each of the protein manufacturing platforms in plants has specific benefits and drawbacks. We have engaged in comparing some of these production systems with respect to their performance: protein yield and quality. Using a specific tester protein (aprotinin), it was shown that functional aprotinin can be manufactured in plants in substantial amounts, as illustrated in this chapter.
Vancanneyt
Guy
G
Bayer BioScience NV, Gent, Belgium.
Dubald
Manuel
M
Schröder
Werner
W
Peters
Jörg
J
Botterman
Johan
J
D000595:Amino Acid Sequence; D007611:Aprotinin / Q000096:biosynthesis* / Q000737:chemistry; D008969:Molecular Sequence Data; D004364:Pharmaceutical Preparations; D030821:Plants, Genetically Modified / Q000235:genetics*; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000737:chemistry; D014026:Nicotiana / Q000235:genetics*; D019076:Transgenes
D004364:Pharmaceutical Preparations; D011994:Recombinant Proteins; D007611:Aprotinin